

מידע לצוות הרפואי

معلومات للطواقم الطبي

Information for Healthcare Professionals

Preparation and Administration

Visually inspect for particulate matter and discoloration. OPDIVO is a clear to opalescent, colorless to pale-yellow solution. Discard if cloudy, discolored, or contains extraneous particulate matter other than a few translucent-to-white, proteinaceous particles. Do not shake.

Preparation

- Withdraw the required volume of OPDIVO and transfer into an intravenous container.
- Dilute OPDIVO with either 0.9% Sodium Chloride Injection, USP or 5% Dextrose Injection, USP to prepare an infusion with a final concentration ranging from 1 mg/mL to 10 mg/mL. The total volume of infusion must not exceed 160 mL.
 - For adult and pediatric patients with body weight 40 kg or greater, do not exceed a total volume of infusion of 160 mL.
 - For adult and pediatric patients with body weight less than 40 kg, do not exceed a total volume of infusion of 4 mL/kg of body weight.
- Mix diluted solution by gentle inversion. Do not shake.
- Discard partially used vials or empty vials of OPDIVO.
- The product does not contain a preservative.
- After preparation, store the diluted solution either:
 - at room temperature and room light for no more than 8 hours from the time of preparation to end of the infusion. Discard diluted solution if not used within 8 hours from the time of preparation; or

- under refrigeration at 2°C to 8°C and protected from light for no more than 7 days from the time of preparation to end of infusion. Discard diluted solution if not used within 7 days from the time of preparation.

- Do not freeze.

Administration

- Administer the infusion, after dilution, over 30 minutes or 60 minutes depending on the dose through an intravenous line containing a sterile, non-pyrogenic, low protein binding in-line filter (pore size of 0.2 micrometer to 1.2 micrometer).
- Administer OPDIVO in combination with other therapeutic agents as follows:
 - With ipilimumab: administer OPDIVO first followed by ipilimumab on the same day.
 - With platinum-doublet chemotherapy: administer OPDIVO first followed by platinum doublet chemotherapy on the same day.
 - With ipilimumab and platinum-doublet chemotherapy: administer OPDIVO first followed by ipilimumab and then platinum-doublet chemotherapy on the same day.
 - With fluoropyrimidine- and platinum-containing chemotherapy: administer OPDIVO first followed by fluoropyrimidine- and platinum-containing chemotherapy on the same day.
- Use separate infusion bags and filters for each infusion.
- Flush the intravenous line at end of infusion.
- Do not co-administer other drugs through the same intravenous line.